LUMISIGHT allergy risk under the microscope in 1,500 patients
NCT ID NCT07572162
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study monitors 1,500 adults with breast cancer who receive LUMISIGHT during lumpectomy surgery. Researchers will track how often serious allergic reactions occur within 60 minutes of injection. No new drug is being tested; the goal is to better understand the safety of this already-approved imaging agent.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LUMISIGHT (pegulicianine)
- What this could lead to
- If successful, this study will provide clearer safety data on allergic reactions to LUMISIGHT, helping doctors manage risks during breast cancer surgery.
- What could go wrong
- This is an observational study, not a treatment trial. It only measures side effects and does not test a new therapy or cure. Results may not change clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?